RDInvesting Provides Investors with Free In-Depth Equity Reports on JAZZ, PRGO, QCOR and VRX

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - News) shares increased 0.58 percent to close at $90.22 a share Tuesday. The stock traded between $90.05 and $91.93 on volume of 510,506 shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a "buy" rating and a price target of $105.00. Shares of Jazz Pharmaceuticals have gained approximately 70.0 percent year-to-date.

Find out more about Jazz Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/JAZZ

Perrigo Company (NYSE:PRGO - News) shares increased 0.59 percent to close at $124.64 a share Tuesday. The stock traded between $124.20 and $124.92 on volume of 622,198 million shares traded. Analysts at CRT Capital have recently initiated coverage on the company with a "buy" rating and a price target of $145.00. Shares of Perrigo have gained approximately 20.0 percent year-to-date.

Find out more about Perrigo including full access to the free equity report at:
www.RDInvesting.com/PRGO

Questcor Pharmaceuticals Inc. (NASDAQ:QCOR - News) shares increased 0.40 percent to close at $65.53 a share Tuesday. The stock traded between $64.59 and $66.20 on volume of 675,812 shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a "neutral" rating and a price target of $71.00. Shares of Questcor Pharmaceuticals have gained approximately 145.0 percent year-to-date.

Find out more about Questcor Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/QCOR

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX - News) shares increased 1.53 percent to close at $102.77 a share Tuesday. The stock traded between $101.66 and $103.40 on volume of 1.23 million shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a "conviction buy" rating and a price target of $130.00. Shares of Valeant Pharmaceuticals have gained approximately 72.0 percent year-to-date.

Find out more about Valeant Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/VRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com